Objective The androgen receptor-targeting drugs abiraterone acetate and enzalutamide
have shown positive results as treatments for metastatic castration-resistant prostate cancer …

Purpose: To compare the effectiveness and safety between abiraterone and enzalutamide in
the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) …

Background Two new drugs, abiraterone and enzalutamide, had recently shown beneficial
effects on survival in patients with metastatic castration-resistant prostate cancer. We …

This study was designed to evaluate the efficacy, tolerability, and sequential administration
of abiraterone acetate (AA) and enzalutamide (Enz) for metastatic castration-resistant …

Various novel androgen receptor (AR) targeting drugs have been developed recently and
have shown beneficial effects on survival in patients with metastatic castration-resistant …

Purpose New therapies with diverse mechanisms of action are available for metastatic
castration-resistant prostate cancer (mCRPC). This study aims to evaluate the effectiveness …

Sequential treatment of androgen receptor axis targeted agents (ARAT), abiraterone acetate
(ABI) and enzalutamide (ENZA), in metastatic castration-resistant prostate cancer (mCRPC) …

Purpose The aim of this study was to evaluate the efficacy of abiraterone in patients with
castration‐resistant metastatic prostate cancer. Materials and methods We retrospectively …

Background Both abiraterone acetate (AA) and enzalutamide are promising agents for
patients with pre-and post-chemotherapy metastatic castration-resistant prostate cancer …

Background Abiraterone and enzalutamide are widely used as first-line treatment for
metastatic castration-resistant prostate cancer (mCRPC); however, their efficacy in mCRPC …